Theseus Pharmaceuticals, Inc. (THRX) Analyst Estimates Annual - Discounting Cash Flows
Theseus Pharmaceuticals, Inc.
THRX (NASDAQ)

* (except for per share items) of USD
Period Ending: 2025
12-31
2024
12-31
2023
12-31
2022
12-31
Number of Analysts 0 0 0 0
Estimated Revenue
Low 0 0 0 0
Average 0 0 0 0
High 0 0 0 0
Estimated EBITDA
Low None None None None
Average None None None None
High None None None None
Estimated EBIT
Low None None None None
Average None None None None
High None None None None
Estimated Net Income
Low -94.69 -72.36 -58.89 -63.89
Average -88.55 -70.46 -61.37 -50.81
High -23.86 -41.18 -50.81 -37.18
Estimated SGA Expenses
Low None None None None
Average None None None None
High None None None None
Estimated EPS
Low -2.46 -1.88 -1.53 -1.66
Average -1.5 -1.51 -1.43 -1.32
High -0.62 -1.07 -1.32 -0.966
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us